Fabio Antonio Gaiotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fabio Antonio Gaiotto has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Bacal
Universidade de São Paulo
5 shared publications - Samuel Padovani Steffen
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Unidade de Transplante, Departamento de Cirurgia Cardiovascular
5 shared publications - Alvaro Perazzo
Universidade de São Paulo
4 shared publications - Fabiana Goulart Marcondes Braga
Universidade de São Paulo
4 shared publications - Luis Fernando Bernal da Costa Seguro
Universidade de São Paulo Faculdade de Medicina Núcleo de Transplante do Instituto do Coração do Hospital das Clínicas São Paulo AP Brazil Núcleo de Transplante do Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, AP - Brazil
4 shared publications - Mônica Samuel Avila
Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade Medicina, Universidade de Sao Paulo, Brazil
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Diretriz Brasileira de Cardiogeriatria – 2026
Sumário […] Diretriz Brasileira de Cardiogeriatria – 2026 Sumário […] Diretriz Brasileira de Cardiogeriatria – 2026
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Open AccessDiretriz Brasileira de Cardiogeriatria – 2026
Sumário […] Diretriz Brasileira de Cardiogeriatria – 2026 Sumário […] Diretriz Brasileira de Cardiogeriatria – 2026
- Open Access
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Diretriz Brasileira de Valvopatias – 2026
Sumário […] Diretriz Brasileira de Valvopatias – 2026 Sumário […] Diretriz Brasileira de Valvopatias – 2026
- 7 October 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (10)
Open AccessDiretriz Brasileira de Valvopatias – 2026
Sumário […] Diretriz Brasileira de Valvopatias – 2026 Sumário […] Diretriz Brasileira de Valvopatias – 2026
- Open Access
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Mudança dos Padrões da Mortalidade Fora do Hospital e da Perda Prematura de Vida em Cardiomiopatias: Um Estudo Nacional Baseado em População
Fundamento: As cardiomiopatias são uma importante causa de mortalidade cardiovascular, apresentando fenótipos dependentes da idade que variam desde morte súbita cardíaca (MSC) até insuficiência cardíaca progressiva. Apesar da queda nas taxas de mortalidade, lacunas na prevenção e no acesso a terapias avançadas podem se manifestar como mudanças no local do óbito e persistência de mortalidade prematura. Objetivos: Avaliar tendências temporais da mortalidade relacionada às cardiomiopatias no Brasil, examinar padrões etários no local do óbito e quantificar a mortalidade prematura por meio dos anos de vida perdidos (AVP). Métodos: Este estudo ecológico nacional, baseado em população, analisou 369 570 óbitos no Brasil (1996–2024) em que a cardiomiopatia (CID-10 I42) foi a causa básica. Tendências temporais foram avaliadas por regressão de Poisson, e associações entre idade e local do óbito foram estimadas por razões de chances (OR). Os AVP foram calculados utilizando tábuas de vida nacionais. Resultados: A mortalidade ajustada por idade diminuiu 1,7% ao ano (p<0,001). Óbitos hospitalares caíram de 75% para 43%, enquanto óbitos domiciliares aumentaram de 20% para 38%, com ponto de inflexão significativo por volta de 2011. Óbitos em vias públicas, usados como proxy de MSC, foram mais frequentes entre adultos de 20–39 anos (4,8%) do que entre aqueles com ≥60 anos (0,8%; OR 2,88; IC 95% 2,68–3,10). O total de AVP atingiu 6,83 milhões de anos. Indivíduos de 20–39 anos representaram apenas 5,5% dos óbitos, mas contribuíram com 12,8% dos AVP totais, com média de 42,9 anos perdidos por óbito. Conclusões: Apesar da queda na mortalidade, óbitos fora do ambiente hospitalar tornaram-se mais frequentes. O excesso de AVP entre adultos jovens evidencia lacunas na prevenção da MSC. Estratégias específicas por faixa etária são necessárias para reduzir a mortalidade prematura.
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Open AccessMudança dos Padrões da Mortalidade Fora do Hospital e da Perda Prematura de Vida em Cardiomiopatias: Um Estudo Nacional Baseado em População
Fundamento: As cardiomiopatias são uma importante causa de mortalidade cardiovascular, apresentando fenótipos dependentes da idade que variam desde morte súbita cardíaca (MSC) até insuficiência cardíaca progressiva. Apesar da queda nas taxas de mortalidade, lacunas na prevenção e no acesso a terapias avançadas podem se manifestar como mudanças no local do óbito e persistência de mortalidade prematura. Objetivos: Avaliar tendências temporais da mortalidade relacionada às cardiomiopatias no Brasil, examinar padrões etários no local do óbito e quantificar a mortalidade prematura por meio dos anos de vida perdidos (AVP). Métodos: Este estudo ecológico nacional, baseado em população, analisou 369 570 óbitos no Brasil (1996–2024) em que a cardiomiopatia (CID-10 I42) foi a causa básica. Tendências temporais foram avaliadas por regressão de Poisson, e associações entre idade e local do óbito foram estimadas por razões de chances (OR). Os AVP foram calculados utilizando tábuas de vida nacionais. Resultados: A mortalidade ajustada por idade diminuiu 1,7% ao ano (p<0,001). Óbitos hospitalares caíram de 75% para 43%, enquanto óbitos domiciliares aumentaram de 20% para 38%, com ponto de inflexão significativo por volta de 2011. Óbitos em vias públicas, usados como proxy de MSC, foram mais frequentes entre adultos de 20–39 anos (4,8%) do que entre aqueles com ≥60 anos (0,8%; OR 2,88; IC 95% 2,68–3,10). O total de AVP atingiu 6,83 milhões de anos. Indivíduos de 20–39 anos representaram apenas 5,5% dos óbitos, mas contribuíram com 12,8% dos AVP totais, com média de 42,9 anos perdidos por óbito. Conclusões: Apesar da queda na mortalidade, óbitos fora do ambiente hospitalar tornaram-se mais frequentes. O excesso de AVP entre adultos jovens evidencia lacunas na prevenção da MSC. Estratégias específicas por faixa etária são necessárias para reduzir a mortalidade prematura.
- Open Access
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Shifting Patterns of Out-Of-Hospital Mortality and Premature Life Loss in Cardiomyopathies: A Nationwide Population-Based Study
Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based [...] Abstract Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Open AccessShifting Patterns of Out-Of-Hospital Mortality and Premature Life Loss in Cardiomyopathies: A Nationwide Population-Based Study
Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based [...] Abstract Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based
- Open Access
- 26 July 2026
- Published by Science Publishing Group in Cardiology and Cardiovascular Research
- Vol. 10 (3) , 96-105
Impact of Intra-aortic Balloon Pump in Advanced Heart Failure and Cardiogenic Shock Pre and Post Heart Transplant
The use of the intra-aortic balloon pump (IABP) in advanced heart failure (HF) and cardiogenic shock (CS) is still under debate. In this study we sought to assess the clinical and hemodynamic outcomes in IABP-treated heart transplantation (HTx) patients as well as its impact on mortality. We retrospectively analyzed patients with advanced HF and CS, admitted in the cardiac intensive care unit (ICU) of our institution, between 2009 and 2020, who underwent HTx. We compared patients treated with IABP pre-HTx with a control (CR) group submitted to HTx without mechanical circulatory support. Propensity Score Matching was used to pair the groups according to relevant clinical covariates. 326 patients were included (IABP= 199; CR= 127). Overall survival was similar in IABP and CR groups at 30 days post-HTx (p=0.459). Clinical conditions improved 96 hours after IABP therapy. Central venous oxygen saturation (ScvO2) increased from 49.9% to 66.85% (p<0.001), and diuresis from 1690.12 mL/24 h to 2193.12 mL/24h (p<0.001). Lactate decreased from 21.91 mg/dl to 12.6 mg/dl (p<0.001) and creatinine from 2.04 mg/dL to 1.72 mg/dL (p=0.301). The use of nitroprusside increased from 58.08 to 63.59% (p=0.154), and norepinephrine decreased from 17.7% to 6.63% (p<0.001). The differences were maintained until HTx. IABP related complications were few. Overall outcomes of IABP in advanced HF and CS as a bridge therapy to HTx are encouraging. The survival rate was similar between the groups and IABP can be considered a safe and effective device with few and manageable complications.
- 26 July 2026
- Published by Science Publishing Group in Cardiology and Cardiovascular Research
- Vol. 10 (3) , 96-105
Open AccessImpact of Intra-aortic Balloon Pump in Advanced Heart Failure and Cardiogenic Shock Pre and Post Heart Transplant
The use of the intra-aortic balloon pump (IABP) in advanced heart failure (HF) and cardiogenic shock (CS) is still under debate. In this study we sought to assess the clinical and hemodynamic outcomes in IABP-treated heart transplantation (HTx) patients as well as its impact on mortality. We retrospectively analyzed patients with advanced HF and CS, admitted in the cardiac intensive care unit (ICU) of our institution, between 2009 and 2020, who underwent HTx. We compared patients treated with IABP pre-HTx with a control (CR) group submitted to HTx without mechanical circulatory support. Propensity Score Matching was used to pair the groups according to relevant clinical covariates. 326 patients were included (IABP= 199; CR= 127). Overall survival was similar in IABP and CR groups at 30 days post-HTx (p=0.459). Clinical conditions improved 96 hours after IABP therapy. Central venous oxygen saturation (ScvO2) increased from 49.9% to 66.85% (p<0.001), and diuresis from 1690.12 mL/24 h to 2193.12 mL/24h (p<0.001). Lactate decreased from 21.91 mg/dl to 12.6 mg/dl (p<0.001) and creatinine from 2.04 mg/dL to 1.72 mg/dL (p=0.301). The use of nitroprusside increased from 58.08 to 63.59% (p=0.154), and norepinephrine decreased from 17.7% to 6.63% (p<0.001). The differences were maintained until HTx. IABP related complications were few. Overall outcomes of IABP in advanced HF and CS as a bridge therapy to HTx are encouraging. The survival rate was similar between the groups and IABP can be considered a safe and effective device with few and manageable complications.
- Open Access
Gene expression analysis of primary graft dysfunction in adult heart transplant recipients: A cohort study
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (6)
History and Application of Mechanical Assist Devices as a Bridge to Heart Transplant: A Review and Perspectives in Brazil
Mechanical circulatory support (MCS) devices have evolved significantly over the past decades and play a vital role in managing end-stage heart failure, especially as a bridge to heart transplantation. From the pioneering heart-lung machines to third-generation ventricular assist devices (VADs), MCS technology has advanced to provide more durable, efficient, and safer options for both shortand long-term support. This review outlines the historical development of mechanical assist devices, the types of available supports - ranging from intra-aortic balloon pumps and extracorporeal membrane oxygenation to implantable devices like HeartMate 3 - and their clinical indications and complications. Special attention is given to right ventricular dysfunction, thromboembolic and hemorrhagic complications, and infections, which remain major challenges in the management of patients with MCS devices.In Brazil, despite the growing evidence supporting MCS in critically ill patients, access remains limited due to financial and systemic constraints. The review explores the current landscape of device availability in the country, national guidelines, cost-effectiveness data, and the impact of recent changes in transplant allocation criteria that prioritize patients receiving mechanical support. Notably, the approval of long-term VADs for destination therapy in the public health system in 2024 marks a significant milestone.This review offers a comprehensive perspective on MCS utilization, highlighting both global advances and Brazil-specific challenges. By identifying gaps in access and proposing future directions, it advocates for expanded use of these life-saving technologies to improve survival and quality of life in advanced heart failure patients.
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (6)
Open AccessHistory and Application of Mechanical Assist Devices as a Bridge to Heart Transplant: A Review and Perspectives in Brazil
Mechanical circulatory support (MCS) devices have evolved significantly over the past decades and play a vital role in managing end-stage heart failure, especially as a bridge to heart transplantation. From the pioneering heart-lung machines to third-generation ventricular assist devices (VADs), MCS technology has advanced to provide more durable, efficient, and safer options for both shortand long-term support. This review outlines the historical development of mechanical assist devices, the types of available supports - ranging from intra-aortic balloon pumps and extracorporeal membrane oxygenation to implantable devices like HeartMate 3 - and their clinical indications and complications. Special attention is given to right ventricular dysfunction, thromboembolic and hemorrhagic complications, and infections, which remain major challenges in the management of patients with MCS devices.In Brazil, despite the growing evidence supporting MCS in critically ill patients, access remains limited due to financial and systemic constraints. The review explores the current landscape of device availability in the country, national guidelines, cost-effectiveness data, and the impact of recent changes in transplant allocation criteria that prioritize patients receiving mechanical support. Notably, the approval of long-term VADs for destination therapy in the public health system in 2024 marks a significant milestone.This review offers a comprehensive perspective on MCS utilization, highlighting both global advances and Brazil-specific challenges. By identifying gaps in access and proposing future directions, it advocates for expanded use of these life-saving technologies to improve survival and quality of life in advanced heart failure patients.
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 152-156
Cognitive Frailty and Depressive Symptoms in Heart Transplant Candidates: Rational and Study Design
Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as [...] Abstract Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 152-156
Cognitive Frailty and Depressive Symptoms in Heart Transplant Candidates: Rational and Study Design
Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as [...] Abstract Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 136-137
Biologic Left Ventricular Assist: A New Strategy for Patients with Advanced Heart Failure with Pulmonary Hypertension
Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or [...] Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 136-137
Biologic Left Ventricular Assist: A New Strategy for Patients with Advanced Heart Failure with Pulmonary Hypertension
Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or [...] Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or
- Open Access
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S328
Challenges in Heart Transplantation During COVID-19 Pandemic in Brazil
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S328
Open AccessChallenges in Heart Transplantation During COVID-19 Pandemic in Brazil